Summary of Clarivate's Earnings Call Company Overview - **Company**: Clarivate - **Industry**: Information Services - **Business Segments**: - Intelligence Solutions (over 50% of services) - Workflow Solutions (SaaS) - Tech-Enabled Services (primarily in Intellectual Property) [3][4] Key Business Segments - **Academia and Government**: Accounts for about 50% of business; serves 99% of the world's top 400 institutions [4] - **Intellectual Property**: Represents about one-third of business; serves in-house legal departments and law firms [5] - **Life Sciences and Healthcare**: Provides solutions to top pharma and med tech companies [5] Financial Performance Highlights - **Annual Contract Value (ACV)**: Growth improved from below 1% in 2024 to nearly 2% in 2025; guidance for 2026 is 2%-3% growth [7][8] - **Organic Recurring Revenue Growth**: Expected to accelerate from 0.5% in 2024 to between 1% and 2% in 2025 [9] - **Adjusted EBITDA**: Over $1 billion reported last year; expected profit margin expansion of 200 basis points by 2026 [10] - **Free Cash Flow**: Generated $365 million last year; anticipated to grow to about $400 million this year [11] Strategic Initiatives - **Divestiture of Life Sciences Business**: Aimed at focusing on higher growth segments (A&G and IP) and improving balance sheet quality [12][13] - **Value Creation Plan**: Focus on business model optimization, enhancing sales execution, accelerating innovation, and conducting a strategic review [17][18] - **Recurring Revenue Focus**: Shift from transactional to recurring revenue, aiming for 90% recurring revenue [37][38] AI and Innovation - **AI Integration**: Significant investments in AI across products, including research assistants and workflow agents [20][21] - **Web of Science**: Launch of AI-native platform to enhance analytics and research capabilities [26] - **Efficiency Improvements**: Independent studies show significant efficiency gains from AI implementations [27] Market Dynamics - **A&G Segment**: Improvement in renewal rates and contract value; strong funding for academic research expected to continue [42][43] - **IP Segment Growth Drivers**: Anticipated growth in patent filings due to sustained AI innovation; global patents in force have shown healthy growth [48][50] Capital Allocation - **Deleveraging Focus**: Plans to use free cash flow primarily for debt repayment; potential proceeds from the LS&H sale will also support this [55][56] Future Outlook - **Success Metrics for 2026**: Improved customer engagement with AI solutions, achievement of financial objectives, and continued organic growth in ACV and recurring revenue [57]

Core Insights - Clarivate is experiencing a "positive inflection point" after meeting its full-year financial guidance for the first time since 2019, with nearly 2% organic annual contract value (ACV) growth and over $1 billion in adjusted EBITDA for 2025 [2][5][6] Financial Performance - For 2025, Clarivate reported nearly 2% organic ACV growth, improved organic recurring revenue mix to 88%, and generated over $1 billion in adjusted EBITDA along with $365 million in free cash flow [6][7] - Fourth-quarter revenue was $617 million, with full-year revenue totaling $2.455 billion, primarily influenced by inorganic changes due to divestitures [7] - Adjusted diluted EPS for the fourth quarter was $0.20, reflecting a $0.02 sequential increase, with operating cash flow of $160 million [8] AI Strategy - Clarivate is implementing an "Intelligence Amplified" strategy, focusing on AI assistants and workflow agents, with 97% of revenue derived from proprietary solutions enhanced by AI [2][3][9] - The company has launched 10 AI assistants and AI-native solutions, now utilized by over 4,000 institutions, and expects to release more than 10 additional AI solutions in the coming year [10][12] Business Segments - The Life Sciences & Healthcare (LS&H) business is under review for potential sale to enhance focus on Academia & Government (A&G) and Intellectual Property (IP) markets, although 2026 guidance assumes LS&H will be retained for the full year [4][16] - In A&G, the segment achieved 2% organic ACV growth despite funding challenges, with a shift towards a recurring revenue model [10] - The IP segment is undergoing a turnaround with new leadership and AI product launches, showing a 270 basis points year-over-year improvement in annuities revenue [11] Capital Allocation and Leverage - Clarivate's capital allocation strategy includes $225 million in share repurchases and $200 million in bond retirements, maintaining net leverage at approximately four times [14][15] - For 2026, the company aims for 2-3% organic ACV growth, margin expansion to nearly 43%, and a free cash flow target of approximately $400 million [3][17]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $617 million, bringing the full year total to $2.455 billion, with changes driven entirely by inorganic factors due to business disposals [15] - Full year net income improved by $436 million compared to the previous year, primarily due to the absence of non-cash impairment charges and lower income tax and interest expenses [15] - Adjusted diluted EPS increased by $0.02 sequentially to $0.20 [15] - Free cash flow for the full year reached $365 million, reflecting a 2% growth over the prior year [19] Business Line Data and Key Metrics Changes - The Academia and Government segment achieved 2% organic ACV growth, with 93% of revenue now from proprietary solutions [10] - The Intellectual Property business saw a 270 basis points year-over-year improvement in annuities revenue, indicating stronger execution [12] - Life Sciences & Healthcare reported significant adoption of AI solutions, with 11,000 global active users leveraging AI research assistants [12] Market Data and Key Metrics Changes - The company reported stable revenue retention rates of 93% and expects organic annual contract value growth of 2%-3% for 2026 [13][21] - The anticipated decline in revenue due to strategic disposals is expected to be approximately $100 million, with organic recurring revenue mix improving to between 88% and 90% [21][23] Company Strategy and Development Direction - The company is focusing on selling its Life Sciences & Healthcare business to enhance emphasis on the A&G and IP markets and strengthen its balance sheet [5][49] - The AI strategy is centered on leveraging proprietary data and domain expertise to enhance product offerings, with 97% of revenue derived from proprietary assets [6][42] - The company aims to maximize shareholder value through portfolio simplification and disciplined capital allocation [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, expecting continued improvement in key financial metrics and organic growth acceleration supported by AI innovation [14][13] - The company acknowledges market concerns regarding AI disruption but believes its proprietary business model provides a significant competitive advantage [5][6] Other Important Information - The company has initiated a process to sell its Life Sciences & Healthcare segment, which is expected to create shareholder value and allow for a more focused operational execution across A&G and IP segments [5][49] - The company plans to continue investing in product innovation while also focusing on cost efficiencies to improve capital spending [27] Q&A Session Summary Question: Monetization model for subscriptions and AI products - Management confirmed that the subscription model is evolving, with a focus on upselling AI innovations and transitioning to more subscription-based products [32][33] Question: Revenue from proprietary data and tech-enabled workflows - Management clarified that 97% of revenue comes from proprietary data, with a significant portion from information services and enterprise software [42] Question: Considerations for selling Life Sciences and Healthcare business - The decision was based on the goal of creating shareholder value and focusing on the A&G and IP segments, which have synergies [48][49] Question: Strategic synergies between IP and A&G segments - Management highlighted the benefits of shared content and technology platforms between the two segments, which can enhance innovation and operational execution [53][56] Question: Returning the IP segment to organic revenue growth - Management expressed confidence in the IP segment's turnaround, citing strong assets and a focus on innovation and execution [60][62] Question: Capital allocation priorities - Management indicated a focus on deleveraging while also considering stock buybacks, emphasizing the attractive free cash flow yield [68][70] Question: Price realization and revenue growth composition - Management noted that improvements in ACV and recurring revenue growth are primarily driven by volume rather than price increases [72][75]